| 纯度 | >90%SDS-PAGE. |
| 种属 | Human |
| 靶点 | LAMa2 |
| Uniprot No | P24043 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 3013-3122aa |
| 氨基酸序列 | DAGVPGHLCDGQWHKVTANKIKHRIELTVDGNQVEAQSPNPASTSADTND PVFVGGFPDDLKQFGLTTSIPFRGCIRSLKLTKGTGKPLEVNFAKALELR GVQPVSCPAN |
| 预测分子量 | 38 kDa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是关于LAMA2重组蛋白的模拟参考文献示例(实际文献需根据具体研究查询)：
---
1. **文献名称**：*Recombinant Laminin α2 Chain Expression and Functional Characterization*
**作者**：Yurchenco PD, et al.
**摘要**：研究通过哺乳动物细胞系统成功表达重组LAMA2蛋白，验证其与整合素受体的结合能力，并证实其在促进神经元轴突生长中的生物学活性。
2. **文献名称**：*LAMA2-deficient muscular dystrophy model rescued by recombinant protein therapy*
**作者**：Miyagoe-Suzuki Y, et al.
**摘要**：在小鼠模型中，重组LAMA2蛋白通过系统性递送改善了先天性肌营养不良症的表型，恢复了肌肉基底膜的完整性并减少纤维化。
3. **文献名称**：*Structural insights into LAMA2-mediated cell adhesion*
**作者**：Hohenester E, et al.
**摘要**：通过X射线晶体学解析重组LAMA2蛋白的三维结构，揭示了其与层粘连蛋白其他亚基(β1/γ1)的相互作用界面及细胞粘附功能机制。
4. **文献名称**：*Recombinant LAMA2 enhances stem cell differentiation in vitro*
**作者**：Domogatskaya A, et al.
**摘要**：证明重组LAMA2蛋白可作为基质涂层促进多能干细胞向骨骼肌细胞分化，为体外组织工程提供新型生物材料。
---
注：以上为示例性内容，实际文献需通过PubMed或学术数据库检索确认。
**Background of LAMa2 Recombinant Protein**
LAMa2 (Laminin subunit alpha-2) is a critical component of laminin-211 (formerly merosin), a heterotrimeric glycoprotein essential for the structural and functional integrity of the extracellular matrix (ECM). Laminins are pivotal in maintaining tissue architecture, cell adhesion, differentiation, and signaling. Specifically, LAMa2 is highly expressed in the basement membranes of skeletal muscle, Schwann cells, and the nervous system, where it interacts with cell surface receptors like integrins and dystroglycans to mediate ECM-cell communication.
Mutations in the *LAMA2* gene are linked to congenital muscular dystrophy type 1A (MDC1A), a severe neuromuscular disorder characterized by muscle weakness, respiratory complications, and delayed motor development. The absence or dysfunction of LAMa2 disrupts muscle fiber stability and regeneration, highlighting its therapeutic relevance.
Recombinant LAMa2 protein is engineered using biotechnological platforms (e.g., mammalian or insect cell systems) to mimic the native protein’s functional domains. This recombinant form retains binding capacity for ECM components and receptors, enabling its use in *in vitro* and *in vivo* studies to explore disease mechanisms, muscle regeneration, and potential gene or protein replacement therapies.
Research applications include developing 3D cell culture models, testing drug candidates for MDC1A, and optimizing biomaterials for tissue engineering. Additionally, recombinant LAMa2 serves as a critical reagent for antibody production and diagnostic assays targeting laminin-related pathologies.
Overall, LAMa2 recombinant protein bridges translational research and therapeutic innovation, offering insights into ECM biology and avenues for treating neuromuscular disorders. Its production underscores the intersection of molecular biology, disease modeling, and regenerative medicine.
×
